Pharmigene Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Sophia Zhan
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -NT$93m |
| Mar 31 2024 | n/a | n/a | -NT$83m |
| Dec 31 2023 | n/a | n/a | -NT$73m |
| Sep 30 2023 | n/a | n/a | -NT$61m |
| Jun 30 2023 | n/a | n/a | -NT$48m |
| Mar 31 2023 | n/a | n/a | -NT$46m |
| Dec 31 2022 | n/a | n/a | -NT$43m |
| Sep 30 2022 | n/a | n/a | -NT$40m |
| Jun 30 2022 | n/a | n/a | -NT$37m |
| Mar 31 2022 | n/a | n/a | -NT$30m |
| Dec 31 2021 | NT$1m | NT$1m | -NT$23m |
Compensation vs Market: Insufficient data to establish whether Sophia's total compensation is reasonable compared to companies of similar size in the TW market.
Compensation vs Earnings: Insufficient data to compare Sophia's compensation with company performance.
CEO
Sophia Zhan (65 yo)
no data
Tenure
NT$1,082,000
Compensation
Ms. Fuhui Zhan, also known as Sophia, is Chairman, Representative Director, GM & CEO of Pharmigene, Inc.